Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users

Annals of Internal Medicine

Volumn 155, Issue 8, 2011, Pages

  Singh, S ^a   Brophy, James M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; NOTE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT;

EID: 80054731687     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-8-201110180-02005     Document Type: Note

References (3)

1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011;(2):CD006103.
2. Brophy JM. ACP Journal Club: Review: Varenicline is better than placebo or bupropion, but not clearly different from the nicotine patch, for smoking abstinence [Comment]. Ann Intern Med. 2011;154(8):JC4-4.
3. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ. 2011;183:1359-66.